



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

4th Edition

# MM01

## Molecular Testing for Heritable Genetics and Specimen Identification

Sample

This guideline provides recommendations for detecting and reporting genetic variation associated with heritable conditions.

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Molecular Testing for Heritable Genetics and Specimen Identification

Lawrence J. Jennings, MD, PhD, D(ABHI), FCAP  
Alexander Craig Mackinnon, Jr., MD, PhD  
Heddie L. Nichols, PhD  
Arunkanth Ankala, MSc, PhD, FACMG  
Yang Cao, PhD, FACMG, DABMGG  
Kristen Champion, PhD, FACMG  
Basil Elyas, PMP, CSSBB, BSc, MSc  
Robin E. Everts, PhD  
Tracey Freitas, MS, PhD  
Julie Gastier-Foster, PhD, FACMG  
Susan J. Hsiao, MD, PhD  
Alexander Ing, MS, CGC  
Jamey Kain, PhD  
Katrin Leuer, PhD

Marco L. Leung, PhD, FACMG  
Dawn Maghakian, MS, MB(ASCP)<sup>CM</sup>, CGMBS  
Lindsey Mighion, MS, CGC  
Gwyneth K. Olson, BS, M.Phil, MB(ASCP)<sup>CM</sup>  
Cynthe Sims, PhD, HCLD(ABB)  
Elizabeth Spiteri, PhD, FACMG  
Colleen Stevens, PhD  
Alan Stuart, BSc, MLT  
Madina Sukhanova, PhD, FACMG  
Felicidad Valcarcel, BS, MS  
Richard Y. Wang, DO  
Kai Lee Yap, PhD, FACMG  
Yiyong Zhou, PhD  
Val V. Zvereff, MD, PhD, FACMG

## Abstract

Clinical and Laboratory Standards Institute guideline MM01—*Molecular Testing for Heritable Genetics and Specimen Identification* provides general recommendations for all phases of the operation of a molecular diagnostic laboratory focused on detecting and reporting genetic variation associated with heritable conditions. It explains different types of genetic variation, along with the corresponding standardized nomenclature. Various methods of detecting and characterizing genetic variants are described, as well as test-specific requirements for validation and quality assurance. This guideline also discusses special considerations for analyzing and reporting genetic variation associated with heritable conditions.

Clinical and Laboratory Standards Institute (CLSI). *Molecular Testing for Heritable Genetics and Specimen Identification*. 4th ed. CLSI guideline MM01 (ISBN 978-1-68440-189-5 [Print]; ISBN 978-1-68440-190-1 [Electronic]). Clinical and Laboratory Standards Institute, USA, 2023.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org).

**If you or your organization is not a member and would like to become one, or to request a copy of the catalog, contact us at:**

**P:** +1.610.688.0100 **F:** +1.610.688.0700 **E:** [customerservice@clsi.org](mailto:customerservice@clsi.org) **W:** [www.clsi.org](http://www.clsi.org)

Copyright ©2023 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, derivative product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedures manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

## Suggested Citation

CLSI. *Molecular Testing for Heritable Genetics and Specimen Identification*. 4th ed. CLSI guideline MM01. Clinical and Laboratory Standards Institute, USA, 2023.

### Previous Editions:

December 1997, April 2000, June 2006, May 2012

MM01-Ed4

ISBN 978-1-68440-189-5 (Print)

ISBN 978-1-68440-190-1 (Electronic)

ISSN 1558-6502 (Print)

ISSN 2162-2914 (Electronic)

Volume 43, Number 13

# Contents

Abstract .....	i
Committee Membership .....	iii
Foreword .....	vii
<b>Chapter 1: Introduction .....</b>	<b>1</b>
1.1 Scope .....	2
1.2 Background .....	2
1.3 Standard Precautions .....	3
1.4 Terminology .....	3
<b>Chapter 2: Path of Workflow .....</b>	<b>13</b>
<b>Chapter 3: Genetic Variation and Nomenclature .....</b>	<b>15</b>
3.1 Overview of Genetic Variation .....	16
3.2 Chromosomal and Structural Variants .....	16
3.3 Nucleotide Variants .....	23
3.4 Mitochondrial DNA Variants and Heteroplasmy .....	31
3.5 Epigenetics .....	35
<b>Chapter 4: Methods for Detection of Genetic Variation .....</b>	<b>37</b>
4.1 Overview of Molecular Methods .....	38
4.2 Methods to Detect Chromosomal and Structural Variants .....	42
4.3 Methods to Detect Nucleotide Variants .....	45
4.4 RNA Analysis .....	61
4.5 Methylation Analysis .....	62
<b>Chapter 5: Analytical Validation, Clinical Validation, and Clinical Utility .....</b>	<b>65</b>
5.1 Overview .....	66
5.2 Analytical Validation .....	67
5.3 Clinical Validation .....	72
5.4 Clinical Utility .....	78
<b>Chapter 6: Quality System Essentials .....</b>	<b>79</b>
6.1 Quality System Components of Molecular Testing .....	80
6.2 Laboratory-Developed Test Considerations .....	82
6.3 Appropriate and Actionable Quality Control Monitoring .....	84
6.4 Continual Improvement .....	87

## Contents (Continued)

<b>Chapter 7: Preexamination</b>	<b>91</b>
7.1 Considerations for Genetic Testing: Ethical, Privacy, and Financial	92
7.2 Preexamination Genetic Consultation	93
7.3 Specimen Collection, Transport, Storage, and Tracking	96
7.4 Specimen Accessioning	99
7.5 Sample Processing	101
7.6 Sample Storage and Retention	103
7.7 Preexamination Quality Considerations	103
<b>Chapter 8: Examination</b>	<b>105</b>
8.1 Process Control	106
8.2 Provenance Testing	107
8.3 Analysis and Interpretation of Sequence Variants	109
8.4 Bioinformatics Pipeline	110
<b>Chapter 9: Postexamination</b>	<b>115</b>
9.1 Laboratory Records of Molecular Test Results	116
9.2 Laboratory Reports for Molecular Tests	117
9.3 Confidentiality of Molecular Laboratory Reports	120
9.4 Retention and Security of Molecular Laboratory Records	121
9.5 Duty to Reanalyze and Recontact After Issuing Molecular Reports	122
9.6 Postexamination Genetic Consultation	124
9.7 Sample Retention for Molecular Testing	124
9.8 Data Management for Molecular Testing	125
<b>Chapter 10: Conclusion</b>	<b>127</b>
<b>Chapter 11: Supplemental Information</b>	<b>129</b>
<b>References</b>	130
<b>Appendix A.</b> Example of a Failure Modes and Effects Analysis	147
<b>Appendix B.</b> Bayesian Calculations	153
<b>Appendix C.</b> Molecular Genetic Report Examples	156
<b>The Quality Management System Approach</b>	160

## Foreword

Profound technical advances in data acquisition and data analysis have propelled clinical genetic testing to the forefront of laboratory medicine and delivered the era of precision medicine. As a result, many medical laboratories routinely interrogate the entire genome to screen for, monitor, and/or diagnose health disorders; assess well-being; and treat medical conditions. The success of modern genetic testing relies on the proper use of complex analytics and bioinformatics.

This edition of MM01 focuses exclusively on genetic variation associated with heritable conditions. It is intended for use by laboratory staff who oversee all clinical, scientific, and/or operational aspects of the molecular laboratory. Individuals in these roles are responsible for introducing, developing, validating, implementing, and interpreting laboratory tests in the safest, most efficient, and most cost-effective manner possible. To this end, MM01 includes guidance on maintaining the highest standards of quality through robust QC systems.

### Overview of Changes

This guideline replaces the previous edition of the approved guideline, MM01-A3, published in 2012. Several changes were made in this edition, including:

- Removing information on oncology markers and somatic or acquired genetic signatures associated with nonhematological cancers
  - See CLSI documents MM05,<sup>1</sup> MM21,<sup>2</sup> and MM23<sup>3</sup> for information on these topics.
- Updating the types of heritable genetic variation and nomenclature, including mitochondrial and epigenetic disorders (see CLSI document MM09<sup>4</sup>)
- Revising methods and technologies, including next-generation sequencing for detection of genetic variation
- Updating considerations for preexamination, examination, and postexamination processes, with a focus on challenges posed by rare, heritable diseases
- Adding special considerations for accurate reporting and interpretation of carrier screening and noninvasive prenatal testing
- Adding special considerations for bioinformatics and genetic counseling

**NOTE:** The content of this guideline is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

#### KEY WORDS

cytogenetics

epigenetics

genetic disease

genetic variation

methylation

molecular diagnostic test

next-generation sequencing

nucleic acid

# Chapter 1

## Introduction

Sample

# Molecular Testing for Heritable Genetics and Specimen Identification

---

## 1 Introduction

### 1.1 Scope

This guideline has been revised by experienced molecular laboratory professionals to focus on germline genetic diagnostic testing. It provides information for laboratories implementing molecular assays for inherited disorders, including both distributed test systems authorized by applicable regulatory agencies and complex laboratory-developed tests (LDTs). This guideline is intended for use by experienced laboratory directors, supervisors, and manufacturers involved in assay development, validation, verification, and interpretation of molecular testing.

Because molecular diagnostics is multidisciplinary in nature, this guideline provides an overview of the subspecialties that use similar technology or performance specification details. New to this edition are clinical applications of genetic identity testing. These applications include monitoring bone marrow transplant engraftment in hematopoietic stem cell transplantation, tracing sample provenance, and detecting sample contamination. Owing to advances in preimplantation diagnostics and prenatal testing, descriptions of noninvasive and cell-free DNA (cfDNA) detection methods are included.

This guideline does not cover biochemical genetics, paternity and forensics testing, blood banking, or detection of bioterrorism agents that require biosafety levels 3 or higher.

### 1.2 Background

Molecular testing has become essential for assessing a growing number of heritable disorders and pharmacogenetic responses. Genotyping can provide useful indicators of disease diagnosis, prognosis, and progression; guide treatment selection and response; and interrogate targets for gene-specific therapies. Genetic testing can be used in the prenatal setting to screen for and diagnose either suspected or at-risk disorders. In the postnatal setting, genetic testing is routinely used for newborn screening and for diagnosis of suspected disorders. In the pediatric and adult settings, in addition to diagnostics, genetic testing is used for carrier screening, presymptomatic or predictive testing, or assessment of potential treatment response.

Although sensitivity, or threshold of detection, is essential to quantitative testing for genetic signatures of acquired diseases, this guideline primarily focuses on qualitative molecular testing. CLSI document MM06<sup>5</sup> discusses quantitative molecular methods that are applicable to detecting acquired genetic variations in neoplasias, such as linearity and measuring interval, lower limit of detection (LLoD) and lower limit of quantitation, results outside the measuring interval, and technologies used in molecular quantification.

When a molecular test is performed, laboratories should consider the preexamination, examination, and postexamination factors discussed in this guideline. In addition, it is important that the test methodology and results interpretation be based on the test's indication and application. Laboratories should also consider ethical concerns associated with genetic testing and the privacy of genetic information.

Securing qualified and competent personnel at all levels is key to producing accurate and timely medical laboratory test results. Specific qualifications and responsibilities vary from region to region. However, to ensure all personnel have the appropriate skills to perform their jobs competently, medical laboratories should have



## 2 Path of Workflow

Figure 1 depicts the processes of developing and performing molecular tests for heritable conditions.



Abbreviation: QSE, quality system essential.

<sup>a</sup> Three basic symbols are used in this process flow chart: oval (signifies the beginning or end of a process), arrow (connects process activities), box (designates process activities).

**Figure 1. Processes for Developing and Performing Molecular Tests for Heritable Conditions<sup>a</sup>**

## Appendix A. (Continued)

Table A3. (Continued)

Risk Item Number	Mitigation (by design)	Mitigation (by process)	Mitigation (by use)	Is Risk Reduced to Lowest Possible Level (postmitigation)? (If no, additional mitigation measures applied)	Justification for Any Remaining Risk	Evidence of Effectiveness for All Mitigations Implemented
R-0003	<ul style="list-style-type: none"> <li>Analytical validation demonstrated 99.9% sensitivity and 99.6% specificity for all reported genotypes.</li> <li>Batch QC includes positive synthetic QC samples for the 10 most prevalent mutations, a rotating set of 2 extracted DNA QC samples for the additional mutations, and a negative QC sample.</li> <li>Outcomes are tracked.</li> </ul>	N/A	N/A	<ul style="list-style-type: none"> <li>D = 5, unlikely before harm</li> <li>O = 1, apparently random</li> <li>S = 10, customer satisfaction, potential for permanent harm</li> <li>Score = 50, intermediate risk</li> </ul>	Risk cannot be completely eliminated, but mitigations have improved detectability and decreased likely occurrence.	6 months after assay launch, there has been 1 customer complaint of an inaccurate test result (0.001% of test volume), which is within analytical performance claims. In this case, an investigation determined, and an orthogonal method confirmed, that patient had a variation that affects annealing in upstream primer sequence, which likely caused a false-negative result. Mitigations were effective.

# Discover How CLSI Can Improve Your Organization



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

*The leading source for the latest medical laboratory standards.*



CLSI membership lets you directly impact best practice standards used to improve patient care worldwide—standards you use every day. Membership provides you with standards access, volunteering opportunities, influence in the standards development process, networking opportunities, discounts, and more.

Discover the membership option for you at [clsi.org/join](https://clsi.org/join).



Our educational and training programs provide convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources and in-person trainings that make learning stress-free and convenient for you and your staff.

See our current offerings at [clsi.org/global-training](https://clsi.org/global-training).



Ensure high-quality laboratory testing with CLSI standards. eCLIPSE Ultimate Access™, our complete online library of standards, makes it easy for you and your staff to quickly find the CLSI resources you need. Read, search, link, annotate, bookmark, and share notes with your staff, all within one easy-to-use platform.

Learn more at [clsi.org/eCLIPSE](https://clsi.org/eCLIPSE).

# Sample



CLINICAL AND  
LABORATORY  
STANDARDS  
INSTITUTE®

PRINT ISBN 978-1-68440-189-5

ELECTRONIC ISBN 978-1-68440-190-1

MM01-Ed4